Arthur Allen, Gregory Piazza, Margaret Fang/LinkedIn
Sep 12, 2025, 15:44
Long-Term Apixaban Use for Provoked VTE: Focus on HI-PRO Trial by Arthur Allen, Margaret Fang and Gregory Piazza
Anticoagulation Forum shared on LinkedIn:
”Join us for our free October webinar: Emerging Evidence: Long-term oral anticoagulation following provoked VTE? A focus on the HI-PRO Trial
Tuesday, October 7, 2025 | 12:00 PM ET
Join us as expert faculty review findings from the recent HI-PRO Trial on the use of apixaban for extended treatment of provoked venous thromboembolism (VTE).
What you’ll learn:
- Key insights from trial design and results
- Clinical implications for real-world practice
- Patient selection considerations for extended therapy
Faculty:
Arthur Allen, PharmD, CACP – Salt Lake City Va Health Care System
Margaret Fang, MD, MPH – University of California, San Francisco
Gregory Piazza, MD, MS – Brigham and Women’s Hospital”
Register here.
Stay informed on all webinars and seminars in the field of thrombosis with Hemostasis Today.
-
May 8, 2026, 19:37Mostafa Faisal Mohammed Saleh: Exploring the Role of AI and Learning in Monitoring Iron Overload in Beta-Thalassemia
-
May 8, 2026, 19:27Spelile Mutupira: Hemostasis – How the Body Stops Bleeding Naturally
-
May 8, 2026, 19:15Not All TF Activity Assays Measure Tissue Factor – RPTH Journal
-
May 8, 2026, 18:48Carlos Penalillo Pimentel: Detection of Rare Blood Donor Phenotypes During Investigation of Serologic Discrepancies
-
May 8, 2026, 18:23How SCD Affects Daily Life in sub-Saharan Africa? – American Society of Hematology
-
May 8, 2026, 18:03Risk of Thrombosis After Stopping Anticoagulation in APS With aPL Negativization -JTH
-
May 8, 2026, 17:35Gurpreet Kaur Sagoo: A Rare Bone Marrow Failure Syndrome That Challenges Early Diagnosis
-
May 8, 2026, 17:31Edward Lee Carter։ Stroke Prevention Starts in the Emergency Department – but Doesn’t End There
-
May 8, 2026, 17:14Hayder Kadhim: Determinants and Outcomes of OAC Discontinuation in Atrial Fibrillation